Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details)

v3.23.1
Commitments and Contingencies (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Feb. 03, 2020
USD ($)
milestone
Sep. 24, 2018
USD ($)
therapy
milestone
Oct. 31, 2022
USD ($)
Jul. 31, 2019
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2018
unit
$ / shares
Jun. 22, 2021
USD ($)
Jun. 09, 2021
USD ($)
May 28, 2021
USD ($)
Mar. 25, 2021
USD ($)
Operating Leased Assets [Line Items]                      
Employee’s base compensation     $ 1,400                
Selling, general and administrative         $ 20,711 $ 24,658          
Royalty agreement, payment received       $ 2,000              
Period after public launch to terminate agreement       3 years              
Buyout option, percentage of net present value of royalty payments       75.00%              
Aevi                      
Operating Leased Assets [Line Items]                      
Payment for contingent consideration         0            
Aevi                      
Operating Leased Assets [Line Items]                      
Number of contingent consideration milestones | milestone 2                    
Contingent consideration $ 6,500                    
Ichorion                      
Operating Leased Assets [Line Items]                      
Number of contingent consideration milestones | milestone   3                  
Contingent consideration   $ 15,000                  
Payment for contingent consideration           0          
CERC-801, CERC-802, And CERC-803 | Ichorion                      
Operating Leased Assets [Line Items]                      
Number of preclinical therapies | therapy   3                  
CERC-913 | Ichorion                      
Operating Leased Assets [Line Items]                      
Number of preclinical therapies | therapy   1                  
Milestone One | Aevi                      
Operating Leased Assets [Line Items]                      
Contingent consideration 2,000                    
Milestone One | Ichorion                      
Operating Leased Assets [Line Items]                      
Payment for contingent consideration   $ 6,000                  
Milestone Two | Aevi                      
Operating Leased Assets [Line Items]                      
Contingent consideration $ 4,500                    
Milestone Two | Ichorion                      
Operating Leased Assets [Line Items]                      
Payment for contingent consideration   5,000                  
Milestone Three | Ichorion                      
Operating Leased Assets [Line Items]                      
Payment for contingent consideration   $ 4,000       0          
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement                      
Operating Leased Assets [Line Items]                      
Upfront license fee                     $ 10,000
Research and development         0 10,000          
Cumulative expense recognized to date         0            
Percent of payments received from sublicensing                     30.00%
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone One                      
Operating Leased Assets [Line Items]                      
Maximum aggregate milestone payment                     $ 112,500
Kyowa Kirin Co., Ltd. (KKC) | AVTX-002 KKC License Agreement | Milestone Two                      
Operating Leased Assets [Line Items]                      
Maximum aggregate milestone payment                     $ 75,000
Astellas Pharma, Inc. (Astellas) | AVTX-006 Astellas License Agreement                      
Operating Leased Assets [Line Items]                      
Upfront license fee         500            
Maximum aggregate milestone payment         5,500            
Research and development         0 500          
Cumulative expense recognized to date           500          
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement                      
Operating Leased Assets [Line Items]                      
Upfront license fee               $ 400      
Research and development         $ 0 400          
Cumulative expense recognized to date           0          
Patent costs               500      
Selling, general and administrative           500          
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone One                      
Operating Leased Assets [Line Items]                      
Maximum aggregate milestone payment               24,200      
Sanford Burnham Prebys Medical Discovery Institute | AVTX-008 Sanford Burnham Prebys License Agreement | Milestone Two                      
Operating Leased Assets [Line Items]                      
Maximum aggregate milestone payment               $ 50,000      
Alto | AVTX-301 Out-License                      
Operating Leased Assets [Line Items]                      
Maximum proceeds from milestones                   $ 18,600  
Revenue recognized from milestones to date           0          
ES | AVTX-406 License Assignment                      
Operating Leased Assets [Line Items]                      
Revenue recognized from milestones to date           $ 0          
ES | Milestone One | AVTX-406 License Assignment                      
Operating Leased Assets [Line Items]                      
Maximum proceeds from milestones                 $ 6,000    
ES | Milestone Two | AVTX-406 License Assignment                      
Operating Leased Assets [Line Items]                      
Maximum proceeds from milestones                 $ 20,000    
TRIS Pharma | Karbinal Agreement                      
Operating Leased Assets [Line Items]                      
Minimum quantity required | unit             70,000        
Make whole payment per unit (in dollars per share) | $ / shares             $ 30